samedan logo

 
 
spacer
home > ebr > autumn 2002 > biotech investor relations - weathering the storm
PUBLICATIONS
European Biopharmaceutical Review

Biotech Investor Relations - Weathering the Storm

"The drug sector is out of favour...we have had 12 profits warnings in the pharma sector since January 2001 compared with two between 1990 and 2000. This is the worst time ever for pharma and it has impacted the biotech sector." Are these really the worst market conditions yet? Many think they are and it is certainly true that 2002 has so far been a roller coaster ride for investors in the biotech industry. Can companies attract investor support despite the doom and gloom? What should companies be doing to maximise the value of their shares? The biotech sector is suffering from the excesses of 2000 when over US$37 billion (versus US$16 billion in 2001) was raised, as well as from the poor broad market conditions. The market malaise reflects an uncertain outlook for equities in general, especially for high growth/risk sectors such as early stage biotechnology and technology-related stocks.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Mary Clark, Managing Director of Life Sciences Consulting at Thomson Financial

Mary Clark is Managing Director, Life Sciences Consulting at Thomson Financial. She specialises in building proactive investor relations programmes for life sciences companies at all stages of development, ranging from pre-IPO initiatives to expanding the reach of established multinational corporations.
Prior to joining Thomson Financial, Mary was Global Director of Corporate Communications at BTG plc, where she had overall responsibility for its investor relations, PR and media functions.

spacer
Mary Clark
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom

SHORT HILLS, NJ. June 16, 2022--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
More info >>

White Papers

The Use of Stainless Steel Equipment Within Laboratories and Clean Rooms

Teknomek Ltd

Teknomek explains why stainless steel is the material of choice for laboratories and hygienic manufacturing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement